AGN192836

Research use only, not for human use.

AGN192836 (AGN 192836) is a potent, selective α2 adrenergic (alpha 2-adrenoceptor) agonist with EC50 of 8.7, 41 and 6.6 nM for α2A, α2B and α2C receptor, respectively.

AGN192836 (AGN 192836) is a potent, selective α2 adrenergic (alpha 2-adrenoceptor) agonist with EC50 of 8.7, 41 and 6.6 nM for α2A, α2B and α2C receptor, respectively; displays 1200-, 50- and 10-fols selectivity for the α2A-receptor, α2B-receptor, and α2C-receptors relative to the α2C-receptors; demonstrates effectivity for the reduction of intraocular pressure and for the reduction of blood pressure in vivo.

Binding assays demonstrates that AGN 192836 is 1200-fold selective for the α2A-receptor relative to the α1-receptor, 50-fold selective for the α2A-receptor relative to the α2B-receptor, and 10-fold selective for the α2Areceptor relative to the α2C-receptor.

AGN 192836 is equally efficacious when compared to brimonidine for the reduction of intraocular pressure upon topical administration to the rabbit and more efficacious than brimonidine for the reduction of blood pressure upon intravenous administration to monkey.

AGN 192836

Angiogenesis

Adrenergic Receptor

Adrenergic Receptor

Cardiovascular Disease

——

171102-29-7

231.255

C12H13N3O2

>98% (HPLC)

In Vitro:?DMSO : 80 mg/mL (345.95 mM)

CC1=C(C=CC2=C1OCCO2)NC3=NC=CN3

N-(2,3-Dihydro-5-methyl-1,4-benzodioxin-6-yl)-1H-imidazol-2-amine

(-20℃)

With Ice Pack

≥ 2 years